跳至主要内容
临床试验/ISRCTN30128134
ISRCTN30128134已完成未知

Prospective clinical study of Indocyanine-Green dye immune cell imaging in the human eye

niversity of Bristol0 个研究点目标入组 12 人开始时间: 2017年4月12日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
12

研究概览

简要总结

2020 results in https://doi.org/10.1371/journal.pone.0226311 (added 24/02/2020)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. 18 years of age or over with legal capacity to consent
  • 2. Able to travel and attend the full programme within the funded travel cost budget
  • In addition, ocular inclusion criteria must be met:
  • Cohort 1 - recruitment of 8 patients:
  • 1. With likely or suspected Choroidal Neovascular Membrane or Central Serous Retinopathy that clinically requires ICG angiography (with or without combined fluorescein angiography)
  • 2. Macular sub-retinal fluid is present and at least 500µm in diameter on a spectral-domain OCT scan
  • 3. Any obscuring haemorrhage should not exceed more than 50% of the area of the sub-retinal fluid
  • 4. Not due for intravitreal injection or photodynamic therapy within the first 48 hours of the study period
  • Cohort 2 - recruitment of 4 patients:
  • 1. With likely or suspected posterior uveitis or panuveitis that clinically requires ICG angiography (with or without combined fluorescein angiography)
  • 2. Clinically suspected vasculitis
  • 3. No intravitreal therapy has been administered within 3 months prior or will be administered during the study period
  • 4. Mild vitritis only (with a SUN Haze score =2)
  • Cohort 3 - recruitment of 3 healthy control volunteers:
  • 1. No known ocular pathology
  • 2. No known refractive error larger than +3.00 dioptres or -3.00 dioptres spherical equivalent in either eye
  • 3. Self reported normal community optometry examination within one year prior to recruitment
  • 4. Normal colour fundal photography at start of study
  • Cohort 4 - recruitment of 3 patients:
  • 1. Known ocular pathology where ICG angiography is not normally indicated
  • 2. Diagnoses can include Diabetic Macular Oedema, Proliferative Diabetic Retinopathy, cystoid macular oedema, geographic atrophy or other forms of uveitis not included in Cohort 2
  • 3. Patients meeting the criteria for Cohorts 1 and 2 may also be included, but given ICG alone without combined Fluorescein as in the usual standard of care

排除标准

  • 1. Known fluorescein, ICG, iodine or shellfish allergy
  • 2. Any known contraindication to topical Tropicamide and Phenylephrine dilating drops
  • 3. Known renal (eGFR =80 mL/min/1.73m2) or hepatic dysfunction or active disease that in the opinion of the investigator will contraindicate the administration of ICG
  • 4. Unable to be easily imaged on Spectralis, Optos or Topcon retinal imaging machines (e.g. marked kyphosis or physical impairment)
  • 5. Significant media opacity leading to poor image quality. (e.g. vitreous haemorrhage or cataract)
  • 6. Unable to donate a peripheral blood sample or known HIV, Hep B or C
  • 7. Pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation. A pregnancy test will be performed on all female participants of childbearing age prior to ICG injection
  • 8. Each participant may only enter the study once and cannot currently be enrolled in another research trial

研究者

发起方
niversity of Bristol

相似试验

Imaging immune cells in the human eye using... | 临床试验